Current data on predictive markers for antiangiogenic therapy in thoracic tumours

European Respiratory Journal

Volumn 36, Issue 4, 2010, Pages 915-924

  Reinmuth, N ^a   Thomas, M ^a   Meister, M ^a   Schnabel, P A ^b   Kreuter, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adhesion molecules; Angiogenesis; Circulating endothelial cells; Vascular endothelial growth factor

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; DOCETAXEL; E 7080; GEFITINIB; PAZOPANIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC THERAPY; CAPILLARY DENSITY; ENDOTHELIUM; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROMA CELL; THORAX TUMOR; TUMOR BIOPSY; TUMOR CELL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD34; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL ADHESION MOLECULES; ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957846280     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00074009     Document Type: Review

References (95)

1. Yano S, Nishioka Y, Goto H, et al. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003; 94: 479-485.
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
3. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
4. Reinmuth N, Piegelbrock E, Raedel M, et al. Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. Lung Cancer 2007; 55: 53-60.
5. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, et al. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 2001; 91: 1500-1509
6. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-3927.
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
8. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
9. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26: 60-65.
10. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14: 1407-1412.
11. Lind JS, Dingemans AC, Groen HJ, et al. A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27: A8018.
12. Ramalingam SS, Mack PC, Vokes EE, et al. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097). J Clin Oncol 2008; 26: A8078.
13. Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009; 15: 3600-3609.
14. Hanrahan EO, Lin HY, Du DZ, et al. Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25: A7593.
15. Nikolinakos P, Altorki N, Guarino M, et al. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 2008; 26: A7568.
16. Rizvi NA, Kris MG, Miller VA, et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. J Clin Oncol 2008; 26: A8053.
17. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
18. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
19. Ebos JM, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-17074.
20. Coate LE, John T, Tsao MS, et al. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009; 10: 1001-1010.
21. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008; 14: 8019-8026.
22. Zhu CQ, Shih W, Ling CH, et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006; 59: 790-800.
23. Delmotte P, Martin B, Paesmans M, et al. VEGF et survie des patients atteints d'un cancer pulmonaire: revue systématique avec méta-analyse [VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. Rev Mal Respir 2002; 19: 577-584.
24. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002; 38: 1564-1579.
25. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005; 23: 2020-2027.
26. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009; 27: 4027-4034.
27. Emerging Paradigms and Potential Biomarkers of Response and Resistance in Antiangiogenic Therapy of Cancer. In: Educational Book ASCO. Alexandria, Americal Society of Clinical Oncology, 2009; pp. 716-721.
28. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
29. Fox SB, Leek RD, Weekes MP, et al. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995; 177: 275-283.
30. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with stage I lung adenocarcinoma. Cancer 2002; 94: 1083-1093.
31. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-2865.
32. Kreuter M, Kropff M, Fischaleck A, et al. Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 2009; 33: 1383-1388.
33. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002; 87: 694-701. (Pubitemid 35178743)
34. Trivella M, Pezzella F, Pastorino U, et al. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 2007; 8: 488-499.
35. Onn A, Herbst RS. Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol 2007; 8: 460-461.
36. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
37. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-5218.
38. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24: 217-227.
39. Artacho-Perula E, Roldan-Villalobos R, Cruz-Orive LM. Application of the fractionator and vertical slices to estimate total capillary length in skeletal muscle. J Anat 1999; 195: 429-437.
40. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
41. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22: 3080-3090.
42. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008; 49: Suppl. 2, 113S-128S.
43. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000; 89: 475-483.
44. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999; 188: 369-377.
45. Smith NR, James NH, Oakley I, et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 2007; 6: 2198-2208.
46. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-4580.
47. Emlet DR, Brown KA, Kociban DL, et al. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007; 6: 2664-2674.
48. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
49. Ebos JM, Lee CR, Bogdanovic E, et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008; 68: 521-529.
50. Soo RA, McKeegan E, Chen CS, et al. The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome. J Clin Oncol 2008; 26: A14535.
51. Yamada K, Hirata T, Fujiwara Y, et al. Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. J Clin Oncol 2008; 26: A3527.
52. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007; 25: A7526.
53. Janne PA, Wang XF, Krug LM, et al. Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol 2007; 25: A7707.
54. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-3287.
55. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 2008; 28: 223-232.
56. Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517-519.
57. Witz IP. The involvement of selectins and their ligands in tumor-progression. Immunol Lett 2006; 104: 89-93.
58. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-589.
59. Swellam M, Ragab HM, Abdalla NA, et al. Soluble cytokeratin-19 and E-selectin biomarkers: their relevance for lung cancer detection when tested independently or in combinations. Cancer Biomark 2008; 4: 43-54.
60. Guney N, Soydinc HO, Derin D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage nonsmall cell lung cancer. Med Oncol 2008; 25: 194-200.
61. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996; 74: 13-33.
62. Gho YS, Kim PN, Li HC, et al. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 2001; 61: 4253-4257.
63. Grothey A, Heistermann P, Philippou S, et al. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer 1998; 77: 801-807.
64. Blaschuk OW, Rowlands TM. Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev 2000; 19: 1-5.
65. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428.
66. Gory-Faure S, Prandini MH, Pointu H, et al. Role of vascular endothelial-cadherin in vascular morphogenesis. Development 1999; 126: 2093-2102.
67. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032.
68. Han JY, Kim HS, Lee SH, et al. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003; 41: 65-70.
69. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-571.
70. Sato T, Konishi K, Kimura H, et al. Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Anticancer Res 2001; 21: 643-647.
71. 3-integrin in lung and other organs. Am J Physiol Lung Cell Mol Physiol 2000; 278: L217-L226.
72. Goon PK, Lip GY, Boos CJ, et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79-88.
73. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow- derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
74. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
75. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-367.
76. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.
77. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658-3661.
78. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779.
79. + endothelial precursor cells. Circ Res 2001; 88: 167-174.
80. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-353.
81. Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 2006; 66: 7341-7347.
82. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-1787.
83. Duda DG, Cohen KS, Ancukiewicz M, et al. A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase 2 studies of antiangiogenic agents. J Clin Oncol 2008; 26: A3544.
84. Beerepoot LV, Mehra N, Vermaat JS, et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15: 139-145.
85. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108: 452-459.
86. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11: 3514-3522.
87. Ferreira LS, Gerecht S, Shieh HF, et al. Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circ Res 2007; 101: 286-294.
88. Ozdogu H, Sozer O, Boga C, et al. Flow cytometric evaluation of circulating endothelial cells: a new protocol for identifying endothelial cells at several stages of differentiation. Am J Hematol 2007; 82: 706-711.
89. Aoki M, Yasutake M, Murohara T. Derivation of functional endothelial progenitor cells from human umbilical cord blood mononuclear cells isolated by a novel cell filtration device. Stem Cells 2004; 22: 994-1002.
90. Bergsland EK. When does the presence of the target predict response to the targeted agent? J Clin Oncol 2006; 24: 213-216.
91. Hardwick JS, Yang Y, Zhang C, et al. Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol Cancer Ther 2005; 4: 413-425.
92. Reinmuth N, Rensinghoff S, Raedel M, et al. Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells. Int J Oncol 2007; 31: 621-626.
93. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4: 839-849.
94. Lindahl P, Johansson BR, Leveen P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-245.
95. Hasumi Y, Klosowska-Wardega A, Furuhashi M, et al. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007; 121: 2606-2614.